All In Biotech

Drug Trial Radar · NCT06988670

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

Last checked: Nov 19, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Extend Biosciences Inc.Industry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.

Conditions

  • Hypoparathyroidism

Interventions

  • EXT608Drug

    Modified version of parathyroid hormone attached to vitamin D to extend half-life

  • PlaceboOther

    Placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the safety and tolerability of multiple subcutaneous (SC) escalating dose levels of EXT608 in participants with hypoparathyroidism by determining frequency and severity of treatment emergent adverse events and post-dose change in lab resultsTime frame: From enrollment until the end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Trial Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.